{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:21:57Z","timestamp":1785410517230,"version":"3.56.0"},"reference-count":49,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation","doi-asserted-by":"publisher","award":["221021900128-6"],"award-info":[{"award-number":["221021900128-6"]}],"id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]},{"award":["221021900128-6"],"award-info":[{"award-number":["221021900128-6"]}],"id":[{"id":"https:\/\/ror.org\/01p8ehb87","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Heart failure with preserved ejection fraction (HFpEF) has multiple phenotypic manifestations with heterogeneous treatment responses. Objective: To evaluate the effect of sacubitril\/valsartan (Sac\/Val) on functional capacity and cardiac remodeling in overweight\/obese HFpEF patients with concentric left ventricular hypertrophy (LVH). Methods: Sixty-one overweight\/obese HFpEF patients (body mass index \u2265 25 kg\/m2) with hypertensive LVH (LV mass index \u2265 115 g\/m2 for men or \u226594 g\/m2 for women) were randomized to Sac\/Val (100\u2013400 mg a day; n = 30) versus the usual care group (n = 31) for 6 months. Changes in six-minute walk test distance (6MWTD) were the primary outcomes. Secondary outcomes included changes in echocardiographic parameters of cardiac structure and function, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Results: After 6 months of Sac\/Val therapy, 6MWTD increased, and E\/e\u2032 ratio, LV mass index, LA volume index, and NT-proBNP levels decreased compared with the usual care group (p &lt; 0.05 for all). Conclusions: In overweight\/obese patients with HFpEF and LVH, Sac\/Val significantly improved functional capacity and reduced LV mass and filling pressure compared with standard medical therapy.<\/jats:p>","DOI":"10.3390\/jcm15114286","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:25:31Z","timestamp":1780399531000},"page":"4286","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacubitril\/Valsartan Improves Functional Capacity and Reverses LV Remodeling in Obese Patients with Hypertrophic HFpEF: A Randomized Open-Label Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3285-6148","authenticated-orcid":false,"given":"Artem","family":"Ovchinnikov","sequence":"first","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"},{"name":"Department of Clinical Functional Diagnostics, Russian University of Medicine of the Ministry of Health of the Russian Federation, Dolgorukovskaya St., 4, 127006 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-9884","authenticated-orcid":false,"given":"Alexandra","family":"Potekhina","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Shchendrygina","sequence":"additional","affiliation":[{"name":"Department of Inpatient Medicine No. 2, M. Sechenov First Moscow State Medical University, Trubetskaya St., 8-2, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-036X","authenticated-orcid":false,"given":"Olga","family":"Svirida","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7641-5191","authenticated-orcid":false,"given":"Maria","family":"Sobolevskaya","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Blankova","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Glezer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Vladimirsky Moscow Regional Research Clinical Institute, Shchepkina Street, 61\/2, 129110 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fail","family":"Ageev","sequence":"additional","affiliation":[{"name":"Out-Patient Department, National Medical Research Center of Cardiology Named After Academician E.I. Chazov, Academician Chazov St., 15a, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.hfc.2021.02.010","article-title":"Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications","volume":"17","author":"Galli","year":"2021","journal-title":"Heart Fail. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","article-title":"Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile","volume":"62","author":"Neeland","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","article-title":"Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction","volume":"8","author":"Koepp","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/cvr\/cvac125","article-title":"Natriuretic peptide pathways in heart failure: Further therapeutic possibilities","volume":"118","author":"Sangaralingham","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gallo, G., Rubattu, S., Autore, C., and Volpe, M. (2023). Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065131"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic Features of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: Design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ehjci\/jey042","article-title":"Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: A consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging","volume":"19","author":"Badano","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/ehjci\/jeu219","article-title":"Normal values and clinical relevance of left atrial myocardial function analysed by speckle-tracking echocardiography: Multicentre study","volume":"16","author":"Morris","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ejechocard\/jer021","article-title":"Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE\/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography","volume":"12","author":"Lang","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_17","first-page":"418","article-title":"Statins improve functional capacity and restores LV diastolic reserve in patients with heart failure with preserved left ventricular ejection fraction","volume":"21","author":"Ovchinnikov","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide","volume":"37","author":"Miura","year":"2015","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCHEARTFAILURE.113.000885","article-title":"Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation","volume":"7","author":"Nakagawa","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2011.05.042","article-title":"Lipolytic effectts of B-type natriuretic Peptide1\u201332 in adipose tissue of heart failure patients compared with healthy controls","volume":"58","author":"Polak","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/ijo.2015.222","article-title":"Impaired atrial natriuretic peptide-mediated lipolysis in obesity","volume":"40","author":"Petrus","year":"2016","journal-title":"Int. J. Obes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.ijcard.2013.03.015","article-title":"High concentration of C-type natriuretic peptide promotes VEGF-dependent vasculogenesis in the remodeled region of infarcted swine heart with preserved left ventricular ejection fraction","volume":"168","author":"Cabiati","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-Related Heart Failure with a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jacc.2021.07.014","article-title":"Exercise Intolerance in Older Adults with Heart Failure with Preserved Ejection Fraction: JACC State-of-the-Art Review","volume":"78","author":"Pandey","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients with Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of Sacubitril\/Valsartan Compared with Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy","volume":"146","author":"Shah","year":"2022","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, J., Song, Y., and Chen, F. (2024). Evaluating the impact of Sacubitril\/valsartan on diastolic function in patients with heart failure: A systematic review and meta-analysis. Medicine, 103.","DOI":"10.1097\/MD.0000000000037965"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomized controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ehf2.13779","article-title":"Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan","volume":"9","author":"Dini","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2014.03.014","article-title":"Impact of general and central adiposity on ventricular-arterial aging in women and men","volume":"2","author":"Wohlfahrt","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.119.040332","article-title":"Increased Myocardial Stiffness in Patients with High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure with Preserved Ejection Fraction","volume":"141","author":"Hieda","year":"2020","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcmg.2009.10.012","article-title":"The impact of obesity on the left ventricle: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"3","author":"Turkbey","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.14740\/cr813","article-title":"Anti-Hypertensive Effect of Sacubitril\/Valsartan: A Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Soreca","year":"2019","journal-title":"Cardiol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2025.05.004","article-title":"Structural abnormalities and effects of sacubitril\/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial","volume":"289","author":"Kittipibul","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial Biopsy Characterization of Heart Failure with Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCULATIONAHA.109.869628","article-title":"Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures","volume":"120","author":"Paulus","year":"2009","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11897-012-0109-5","article-title":"Molecular and cellular basis for diastolic dysfunction","volume":"9","author":"Franssen","year":"2012","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shi, Y.J., Yang, C.G., Qiao, W.B., Liu, Y.C., Liu, S.Y., and Dong, G.J. (2023). Sacubitril\/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction. Eur. J. Pharmacol., 961.","DOI":"10.1016\/j.ejphar.2023.176170"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang, W., Liu, J., Fu, Y., Ji, H., Fang, Z., Zhou, W., Fan, H., Zhang, Y., Liao, Y., and Yang, T. (2021). Sacubitril\/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.600953"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Mora\u00f1a-Fern\u00e1ndez, S., V\u00e1zquez-Abu\u00edn, X., Arag\u00f3n-Herrera, A., Anido-Varela, L., Garc\u00eda-Seara, J., Otero-Garc\u00eda, \u00d3., Rodr\u00edguez-Penas, D., Campos-Toimil, M., Otero-Santiago, M., and Rodrigues, A. (2024). Cardiometabolic effects of sacubitril\/valsartan in a rat model of heart failure with preserved ejection fraction. Biochem. Pharmacol., 230.","DOI":"10.1016\/j.bcp.2024.116571"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dhawan, R., Mittal, R., Kumar, A., Laller, K.S., Gill, P.S., Rag, A., and Mittal, N. (2025). Sacubitril\/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. World J. Exp. Med., 15.","DOI":"10.5493\/wjem.v15.i4.111542"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of Sacubitril\/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of Sacubitril\/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure with Preserved Ejection Fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.jacc.2017.01.058","article-title":"Estimating Left Ventricular Filling Pressure by Echocardiography","volume":"69","author":"Andersen","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4286\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:18:49Z","timestamp":1780978729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114286"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114286","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}